#18/18/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2.10.02

In re the Application of: Hiroyuki FUJITA

Group Art Unit: 1654

Serial No.: 09/663,709

Examiner: Anish Gupta

Filed: September 18, 2000

P.T.O. Confirmation No.: 4404

For: ANGIOTENSIN CONVERTING ENZYME INHIBITOR

RESPONSE ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION

Commissioner for Patents Washington, D.C. 20231

November 14, 2002

Sir:

In response to the final Office Action dated July 16, 2002, extended to November 16, 2002 by a one-month Petition for Extension of Time, and in addition to the remarks in the Response under 37 CFR 1.116 filed October 15, 2002, the following remarks are respectfully submitted.

RECEIVED

NOV 2 0 2002

TECH CENTER 1600/2900

REQUEST FOR **CONTINUED EXAMINATION (RCE) TRANSMITTAL**

for the continued

		ave on May 29, 2000, provides i on filed on or after June 8, 1995
70	3	
/ NO	1 1 4 2002 W	
/ nu	<u> </u>	
Ex	, Let	· · · · · · · · · · · · · · · · · · ·

Application Number	09/663,709	
Filing Date	September 18, 2000	
First Named Inventor	FUJITA, Hiroyuki	
Group Art Unit	1654	
Name of Examiner	Anish Gupta	
Attorney Docket No.	001200	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. Note: 37 C.F.R. §1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. §1.53 (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar 20, 2000) 1233 Off. Gazette Pat

1.	1. Submission Required Under 37 C.F.R. § 1.114					
a.	\boxtimes	☐ Previously submitted				
	i.	Ø	Consider the amendment(s)/reply under 37 C.F.R. §1.116 previously file (Any unentered amendment(s) referred to above will be entered)	ed on <u>October 15, 2002</u>		
	ii.		Consider the arguments in the Appeal Brief or Reply Brief previously file	led on		
	iii.		Other	_		
b.	\boxtimes	Er	nclosed	-		
	i.		Amendment/Reply	RECEIVED		
	ii.		Affidavit(s)/Declaration(s)	NOV 9 A 2000		
	iii.		Information Disclosure Statement (IDS)	NOV 2 0 2002		
	iv.	×	Other Response Accompanying RCE	TECH CENTER 1600/2900		
2.	2. Miscellaneous					
a.	Suspension of Action on the above-identified application is requested under 37 C.F.R. §1.103(c) for a period of months (period shall not exceed three months; Fee under 37 C.F.R. §1.17(i) required)					
b.	o. ☑ Other <u>Petition for Extension of Time</u>					
3.	3. Fees The RCE fee under 37 C.F.R. §1.17(e) is required by 37 C.F.R. §1.114 when the RCE is filed.					
a.	a. □ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 01-2340					
	i. D RCE fee required under 37 C.F.R. § 1.17 (e)					
	ii. ☐ Extension of Time Fee (37 C.F.R. §§ 1.136 and 1.17)					
	iii.	□ Ot	ther	1.150		
b.	⊠ (Check	in tha mount of $\$850.00$ is enclosed for filing fee and extension of time	mef.		

REQUEST R CONTINUED EXAMINATION (RCE) TRANSMITTAL

TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for the continued examination of a utility or plant application filed on or after June 8, 1995.

PAGE 2



Atty Docket No.

001200

SIGNATURE BY APPLICANT, ATTORNEY, OR AGENT REOUIRED					
Name Daniel A. Geselowitz, Ph.D.	Registration No. 42,573 (agent)				
Signature Sala Sielect	Date November 14, 2002				
CERTIFICATE OF MAILING OR TRANSMISSION					
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an nv lope addressed to Commissioner for Patents, BOX RCE, Washington, D.C. 20231, or facsimile transmitted to th U.S. Patent and Trademark Office on:					
Name					
Signature					